Iterum Therapeutics (ITRM)

• Market cap: $38.7M
• 1 day: 0.00%
• 5 days: -11.81%
• 1 month: -4.27%
• 3 months: -27.27%
• 6 months: -8.20%
• Year to date: -38.80%
• 1 year: -29.56%
• 5 years: -97.98%
• 10 years: -99.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Employees: 9

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

28% more funds holding

Funds holding: 18 [Q3] → 23 (+5) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

1% less capital invested

Capital invested by funds: $2.22M [Q3] → $2.2M (-$23.9K) [Q4]

4.46% less ownership

Funds ownership: 8.99% [Q3] → 4.53% (-4.46%) [Q4]